Regeneron Pharmaceuticals, Inc.

Icahn School of Medicine at Mount Sinai

Omri Gottesman

Aris I Baras

Frederick E Dewey

Jesper Gromada

Xiping Cheng

Noura S Abul-Husn

Yurong Xin

Alexander Li

Alan R Shuldiner

Gregory Hinkle

Stuart Milstein

Suzanne Hartford

Frederic Tremblay

Evangelos Pefanis

Brian Cajes

Jeffrey Reid

Lukas Habegger

Evan Maxwell

Girish N Nadkarni

Jeffrey Staples

Shannon Bruse

Stephen Bartlett Ellis

Shane McCarthy

Erwin Bottinger

Alan Shuldiner

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the HSD17B 13 gene, as well as methods of inhibiting expression of HSD17B13, and methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, using such dsRNA compositions.

17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof

Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B3 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.

HSD17B13 variants and uses thereof

Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B13 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.

IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.

Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1

Provided are compositions related to HSD17B13 variants, including isolated nucleic acids and proteins related to variants of HSD17B13, and cells comprising those nucleic acids and proteins. Also provided are methods related to HSD17B13 variants. Such methods include methods for modifying a cell through use of any combination of nuclease agents, exogenous donor sequences, transcriptional activators, transcriptional repressors, and expression vectors for expressing a recombinant HSD17B13 gene or a nucleic acid encoding an HSD17B13 protein. Also provided are therapeutic and prophylactic methods for treating a subject having or at risk of developing chronic liver disease.

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the HSD17B13 gene, as well as methods of inhibiting expression of HSD17B13, and methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, using such dsRNA compositions.

17&#x3b2;-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof

An example method of diagnosing chronic kidney disease (CKD) includes obtaining an electronic medical record for a patient having medical data. The medical data includes an indication if the patient had been previously diagnosed with CKD, an indication if the patient had previously undergone a kidney transplant, an indication if the patient had previously undergone a renal dialysis procedure, an indication if the patient had previously been diagnosed with another type of kidney disease, one or more glomerular filtration rate (GFR) measurements associated with the patient, an indication if the patient has type 2 diabetes, and/or an indication if the patient has hypertension. The method also includes automatically determining that the patient has CKD or does not have CKD based on the medical data in the electronic record.

Electronic phenotyping technique for diagnosing chronic kidney disease

Growing community of inventors

New York, NY, United States of America

Omri Gottesman